GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
Ucap Cloud Information Technology Co.,Ltd
688228
Yangtze Optical Electronic
688143
CN Stock MarketDetailed Quotes
002370 Zhejiang Yatai Pharmaceutical
- 3.27
- -0.03-0.91%
Market Closed Jan 24 15:00 CST
2.38BMarket Cap-142.17P/E (TTM)
3.31High3.23Low282.78KlotVolume3.30Open3.30Pre Close92.28MTurnover3.88%Turnover RatioLossP/E (Static)728.59MShares4.3852wk High2.95P/B2.38BFloat Cap2.2152wk Low3.63Limit Up728.59MShs Float22.10Historical High2.97Limit Down2.42%Amplitude2.21Historical Low--Dividend TTM3.26Avg Price166.29KlotAsk--Div YieldTTM100Lot Size108.44KlotBid
Zhejiang Yatai Pharmaceutical News
Asia Pacific Pharmaceutical: 2024 Annual Results Forecast
Zhejiang Yatai Pharmaceutical (002370.SZ): Currently, there are no innovative drugs related to influenza.
On January 8, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) stated on the investor interaction platform that the company currently does not have any Innovative Drugs related to influenza, and its main products are antibiotics, gastrointestinal medications, antiviral drugs, cardiovascular drugs, and antipyretic and analgesic pharmaceuticals.
Zhejiang Yatai Pharmaceutical (SZSE:002370 Shareholders Incur Further Losses as Stock Declines 15% This Week, Taking Five-year Losses to 47%
Zhejiang Yatai Pharmaceutical (002370.SZ): Received the approval notification for the supplementary application of injectable Cefoperazone Sodium Pharmaceutical.
On December 13, Gelonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received the "Notification of Approval for Supplemental Application of Pharmaceuticals" issued by the National Medical Products Administration for injectable cefmetazole sodium. Cefmetazole sodium is highly stable against β-lactamase and has strong antibacterial activity against both β-lactamase-producing and non-producing sensitive bacteria. It has good antibacterial effects against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, and is also effective against common Proteus species that are resistant to cephalosporins and penicillin antibiotics.
Zhejiang Yatai Pharmaceutical (002370.SZ): Termination of the funding project for Convertible Bonds.
On December 11, Ge Long Hui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that at the 33rd meeting of the 7th Board of Directors and the 18th meeting of the 7th Supervisory Board held on December 11, 2024, it approved the "Proposal for Terminating the Fundraising Project for Convertible Bonds." 1. The Phase I and II projects of Zhejiang Yatai Pharmaceutical Modern Pharmaceutical Formulations consist of two independent lyophilized powder injection workshops, a penicillin workshop, a solid preparations workshop, a cephalosporin workshop (capsules and powder injections), a patch workshop, a raw and auxiliary materials finished product warehouse, a quality inspection workshop, a Sewerage treatment center, and dormitories.
Zhejiang Yatai Pharmaceutical (002370.SZ): Injectable Pantoprazole Sodium passed the consistency evaluation.
Zhejiang Yatai Pharmaceutical (002370.SZ) announced that the company recently received approval and issuance of the State Food and Drug Administration regarding...
Zhejiang Yatai Pharmaceutical's Diltiazem Hydrochloride Tablets Enter Consistency Evaluation Review Stage
Asia Pacific Pharmaceutical: Report for the third quarter of 2024
zhejiang yatai pharmaceutical (002370.SZ): a net loss of 3.4595 million yuan in the first three quarters.
Gelonghui On October 30th, Zhejiang Yatai Pharmaceutical (002370.SZ) released its third-quarter report for 2024, achieving revenue of 0.307 billion yuan in the first three quarters, a year-on-year increase of 1.65%; net income attributable to the shareholders of the listed company was -3.4595 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -22.5921 million yuan; basic earnings per share was -0.0056 yuan.
Zhejiang Yatai Pharmaceutical (002370.SZ): Plans to sell 100% equity and debt forgiveness of Shanghai Xingaofeng.
On September 9th, GeLonghui reported that Zhejiang Yatai Pharmaceutical (002370.SZ) announced that at the 31st meeting of the seventh board of directors held on September 9th, 2024, it passed the "Proposal on the sale of 100% equity and debt exemption of wholly-owned subsidiary". On September 9th, 2024, the company signed the "Equity Transfer Agreement of Shanghai Xingaofeng Biomedical Co., Ltd." with Ningbo Heyi Culture Media Co., Ltd. (referred to as "Heyi Culture"), transferring 100% equity of Shanghai Xingaofeng Biomedical Co., Ltd. (referred to as "Shanghai Xingaofeng") held by the company to Heyi Culture. Due to Shanghai.
Zhejiang Yatai Pharmaceutical (002370.SZ): Received the acceptance notice of the consistency evaluation of Atorvastatin tablets.
Galion reported on September 6th that zhejiang yatai pharmaceutical (002370.SZ) announced that the company recently received the acceptance notice of the consistency evaluation of Atorvastatin tablets issued by the National Medical Products Administration. Atorvastatin tablets are mainly used to treat hypertension, angina, myocardial infarction, and can also be used for arrhythmia, hyperthyroidism, and pheochromocytoma.
There is a risk of diffusion! WHO has launched a global strategic preparedness, and monkeypox concept stocks have surged in response.
New variant appears.
Zhejiang Yatai Pharmaceutical: Half-year report for the year 2024.
Zhejiang Yatai Pharmaceutical: Summary of Half-Year Report in 2024.
Zhejiang Yatai Pharmaceutical (002370.SZ) released its performance for the first half of the year, with a net income of 5.4752 million yuan, a 72.30% decrease.
zhejiang yatai pharmaceutical (002370.SZ) released the 2024 interim report, during the reporting period, the company achieved revenue...
Zhejiang Yatai Pharmaceutical (002370.SZ): The net income in the first half of the year was 54.752 million yuan, a 72.30% decrease year-on-year.
Gelonghui August 23rd, Zhejiang Yatai Pharmaceutical (002370.SZ) released the 2024 interim report, with revenue of 0.222 billion yuan during the reporting period, a 0.36% year-on-year increase; net income attributable to shareholders of the listed company was 5.4752 million yuan, a 72.30% year-on-year decrease; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -7.8267 million yuan; basic earnings per share was 0.01 yuan.
Zhejiang Yatai Pharmaceutical (002370.SZ): The specification of Cefpodoxime proxetil for injection has been increased and passed the consistency evaluation of generic drugs.
Zhejiang Yatai Pharmaceutical (002370.SZ) has announced that the company recently received approval and issuance from the National Medical Products Administration...
Optimistic Investors Push Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) Shares Up 29% But Growth Is Lacking
Zhejiang Yatai Pharmaceutical (002370.SZ): The controlling shareholder Fubon Group has completed the shareholding of 2.01%.
Zhejiang Yatai Pharmaceutical (002370.SZ) announced that up to the disclosure date of this announcement, the controlling shareholder of the company, Fubon Group, has accumulated an additional 12.27 million shares of the company through the Shenzhen Stock Exchange's centralized bidding trading system, with a total additional investment of 36,364,912.15 yuan, accounting for 2.01% of the total share capital of the company. The shareholding plan has been fully implemented upon completion.
Zhejiang Yatai Pharmaceutical: 2024 Interim Performance Forecast